Joseph McDonald1, Patricia Vega-Fernandez2, Tracy Ting2. 1. Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. joemcdonald93@gmail.com. 2. Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Abstract
BACKGROUND: Childhood-onset systemic lupus erythematosus (cSLE) is a complex autoimmune disorder with multi-organ manifestations and can be associated with other rheumatic diseases including Sjögren's syndrome (SS). Salivary gland ultrasound (SGUS) represents a noninvasive tool to screen for salivary gland disease in rheumatic disease patients. The aims of this cross-sectional study were to determine feasibility of major SGUS in a clinic setting and to identify characteristics in a cohort of cSLE patients (without confirmed SS) that may be associated with salivary gland abnormalities consistent with secondary SS. METHODS: Patients with SLE onset prior to age 18 were recruited. Patients completed questionnaires rating symptoms and underwent major SGUS examination. Disease and demographic differences were compared between cSLE patients with abnormal SGUS vs. cSLE patients with normal SGUS using t-tests and Fisher's exact tests. RESULTS: Thirty-one cSLE patients were recruited, 84% were female, 55% were Caucasian. The average disease duration among all patients was 5 years. Average time to complete the SGUS examination and scoring protocol was 7 min. 35% of SGUS scores were abnormal and significantly associated with IgG level at diagnosis, and anti-Ro and anti-La antibodies. CONCLUSIONS: This is one of the first studies to our knowledge that assesses major SGUS in a cohort of patients with cSLE without prior diagnoses of SS. The SGUS protocol was feasible to perform by rheumatologists in a clinic setting. Although the sample size was small, SGUS abnormalities were identified in one-third of patients. IgG level at diagnosis and anti-Ro and anti-La antibodies may be associated with SGUS abnormalities.
BACKGROUND: Childhood-onset systemic lupus erythematosus (cSLE) is a complex autoimmune disorder with multi-organ manifestations and can be associated with other rheumatic diseases including Sjögren's syndrome (SS). Salivary gland ultrasound (SGUS) represents a noninvasive tool to screen for salivary gland disease in rheumatic diseasepatients. The aims of this cross-sectional study were to determine feasibility of major SGUS in a clinic setting and to identify characteristics in a cohort of cSLE patients (without confirmed SS) that may be associated with salivary gland abnormalities consistent with secondary SS. METHODS:Patients with SLE onset prior to age 18 were recruited. Patients completed questionnaires rating symptoms and underwent major SGUS examination. Disease and demographic differences were compared between cSLE patients with abnormal SGUS vs. cSLE patients with normal SGUS using t-tests and Fisher's exact tests. RESULTS: Thirty-one cSLE patients were recruited, 84% were female, 55% were Caucasian. The average disease duration among all patients was 5 years. Average time to complete the SGUS examination and scoring protocol was 7 min. 35% of SGUS scores were abnormal and significantly associated with IgG level at diagnosis, and anti-Ro and anti-La antibodies. CONCLUSIONS: This is one of the first studies to our knowledge that assesses major SGUS in a cohort of patients with cSLE without prior diagnoses of SS. The SGUS protocol was feasible to perform by rheumatologists in a clinic setting. Although the sample size was small, SGUS abnormalities were identified in one-third of patients. IgG level at diagnosis and anti-Ro and anti-La antibodies may be associated with SGUS abnormalities.
Authors: Sandrine Jousse-Joulin; Maria Antonietta D'Agostino; Celine Nicolas; Esperanza Naredo; Sarah Ohrndorf; Marina Backhaus; Giorgio Tamborrini; Isabelle Chary-Valckenaere; Lene Terslev; Annamaria Iagnocco; Paz Collado; Cristina Hernández-Díaz; Frederique Gandjbakhch; Wolfgang A Schmidt; Georgios Filippou; Christian Dejaco; Martin Helmut Stradner; Mohamed Atia Mortada; Alojzija Hočevar; Stavros Chrysidis; Ghada El Mardenly; Juan José de Agustín; Ralf Thiele; Daryl K MacCarter; Stephanie Finzel; Petra Hanova; Alen Zabotti; Cornelia Glaser; Zarrin Alavi; Daniel Sten Hammenfors; Florence Gatineau; George Aw Bruyn Journal: Ann Rheum Dis Date: 2019-04-29 Impact factor: 19.103
Authors: Raphaèle Seror; Philippe Ravaud; Xavier Mariette; Hendrika Bootsma; Elke Theander; Arne Hansen; Manel Ramos-Casals; Thomas Dörner; Stefano Bombardieri; Eric Hachulla; Johan G Brun; Aike A Kruize; Sonja Praprotnik; Matija Tomsic; Jacques-Eric Gottenberg; Valerie Devauchelle; Salvatore Devita; Cristina Vollenweider; Thomas Mandl; Athanasios Tzioufas; Steven Carsons; Alain Saraux; Nurhan Sutcliffe; Claudio Vitali; Simon J Bowman Journal: Ann Rheum Dis Date: 2011-02-22 Impact factor: 19.103
Authors: Giuliana Maria Concetta La Paglia; Olga Sanchez-Pernaute; Alessia Alunno; Maria José Martínez-Becerra; Fredeswinda Romero-Bueno; Sheila Recuero; Pablo Eder Borges; Ignacio Mahillo-Fernández; Jesús Garrido; Roberto Gerli; Gabriel Herrero-Beaumont; Esperanza Naredo Journal: Clin Rheumatol Date: 2019-11-01 Impact factor: 2.980